Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):477.
doi: 10.21037/atm.2017.10.26.

The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia

Paul Chan  1 , Li Shao  2 , Brian Tomlinson  3   4 , Zhong-Min Liu  5
Affiliations
Editorial

The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia

Paul Chan et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: B Tomlinson has received research funding from Amgen, AstraZeneca, Merck Serono, Merck Sharp and Dohme, Novartis, Pfizer and Roche, and he has acted as consultant, advisor or speaker for Amgen, AstraZeneca, Merck Serono, Merck Sharp and Dohme and Sanofi. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res 2016;118:547-63. 10.1161/CIRCRESAHA.115.306249 - DOI - PubMed
    1. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2:655-66. 10.1016/S2213-8587(13)70191-8 - DOI - PMC - PubMed
    1. Adiels M, Olofsson SO, Taskinen MR, et al. Diabetic dyslipidaemia. Curr Opin Lipidol 2006;17:238-46. 10.1097/01.mol.0000226115.97436.c0 - DOI - PubMed
    1. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-9. 10.1001/jama.2012.366 - DOI - PubMed
    1. Puri R, Nissen SE, Shao M, et al. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. Arterioscler Thromb Vasc Biol 2016;36:2220-8. 10.1161/ATVBAHA.116.307601 - DOI - PubMed